Krystal Biotech, Inc. (KRYS)
322.28
-3.03
(-0.93%)
USD |
NASDAQ |
Oct 02, 16:00
322.46
+0.18
(+0.06%)
After-Hours: 20:00
Krystal Biotech Gross Profit Margin (Quarterly) : 93.46% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.46% |
| March 31, 2026 | 93.26% |
| December 31, 2025 | 92.39% |
| September 30, 2025 | 94.21% |
| June 30, 2025 | 90.93% |
| March 31, 2025 | 92.45% |
| Date | Value |
|---|---|
| December 31, 2024 | 92.83% |
| September 30, 2024 | 90.25% |
| June 30, 2024 | 88.62% |
| March 31, 2024 | 91.10% |
| December 31, 2023 | 89.61% |
| September 30, 2023 | 83.37% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 82.86% |
| Cytokinetics, Inc. | 67.78% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Exelixis, Inc. | 96.71% |
| Regeneron Pharmaceuticals, Inc. | 83.68% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 20.01% |
| Return on Assets | 18.27% |
| Return on Invested Capital | 19.86% |
| Profit Margin (Quarterly) | 45.94% |
| Operating Margin (Quarterly) | 49.00% |
| Return on Net Operating Assets | 72.07% |